How Did BPH Global Achieve Record Seaweed Sales in Indonesia?

BPH Global has reported record sales in its Indonesian seaweed operations alongside completing a $1.1 million capital raise and advancing promising R&D projects. The company is scaling its trading platform and expanding into bio-stimulants and wellness products as it enters 2026.

  • Record monthly seaweed sales in Indonesia with strong rebound after seasonal dip
  • Completed $1.1 million placement in two tranches with attached options
  • Trade finance facility secured to support scaling of seaweed trading operations
  • Strategic supply agreement with Maluku provincial government to expand processing
  • R&D progress includes rare earth element assays, probiotic beverages, and bio-stimulants
An image related to Unknown
Image source middle. ©

Robust Growth in Indonesian Seaweed Trading

BPH Global Limited (ASX, BP8) has delivered a strong performance in its December 2025 quarter, marked by record sales volumes in its Indonesia-based seaweed trading operations. The company’s vertically integrated approach, combining sustainable sourcing with scalable logistics via its Makassar warehouse platform, has driven accelerating commercial momentum. After a seasonal slowdown due to rainy conditions in November, sales rebounded sharply in December, achieving the second highest monthly result since operations began in May 2025.

Aggregate gross sales over the first eight months of trading have now reached approximately A$2.15 million, underscoring the growing market traction of BP8’s seaweed products. The company is progressively shifting towards independent sales through its own Indonesian subsidiary, reducing reliance on third-party cooperation agreements and enhancing operational control and margins.

Capital Raising and Financial Position

BP8 successfully completed a $1.1 million capital raise through a placement of 550 million shares at $0.002 each, accompanied by options exercisable at $0.004. The placement was executed in two tranches, with the second tranche approved by shareholders in November 2025 and funds received during the December quarter. This capital injection, combined with a US$375,000 trade finance facility secured from Singapore-based Equentia Natural Resources, is designed to support the scaling of seaweed procurement and trading activities.

Despite these funding efforts, the company ended the quarter with cash reserves of approximately $598,000, reflecting ongoing investment in operations and R&D. BP8 acknowledges that its current cash runway covers roughly one quarter of operations, but expects revenue growth and further funding initiatives to sustain its business objectives.

Strategic Expansion and Supply Agreements

A key development during the quarter was the execution of a binding commercial framework agreement with the Maluku Provincial Government’s company Perumda Panca Raya. This partnership aims to secure a stable seaweed supply from Maluku, with an initial target of 200 metric tons per month, scaling to 500 tons. BP8 plans to establish a dedicated processing warehouse in Maluku within six months, expanding its operational footprint beyond South Sulawesi and enhancing regional supply chain resilience.

The Maluku agreement also supports BP8’s bio-stimulant development strategy, with collaborative efforts to establish manufacturing facilities and implement sustainable farming practices. This aligns with BP8’s broader vision of leveraging seaweed’s agricultural and environmental benefits.

Advances in Research and Development

BP8 has made notable progress in its R&D programs, appointing aquaculture expert Ms Ifat Mazouz to its advisory board to strengthen commercialisation capabilities. The company’s mineral extraction research has identified measurable concentrations of rare earth elements such as lanthanum, neodymium, and yttrium in seaweed samples from the Johor Strait, as well as copper and other elements in riverbed sediments. These findings support ongoing trials to bioaccumulate valuable minerals from seaweed biomass.

In addition, BP8 is developing seaweed-based natural formulations targeting male vitality and wellness, positioning itself as an early mover in this niche market. The company is also exploring commercialisation pathways for probiotic green seaweed water kefir beverages developed in partnership with Singapore Polytechnic, alongside bio-stimulant formulations aimed at enhancing crop yields.

BP8’s bioremediation initiatives, focused on rehabilitating polluted Indonesian waterways through seaweed’s natural pollutant absorption capabilities, remain a strategic priority. Discussions with Indonesian government bodies continue as the company prepares pilot programs to demonstrate environmental and commercial viability.

Looking Ahead

Entering 2026, BP8 is focused on scaling its seaweed trading volumes, expanding sourcing networks, and deepening customer relationships. The company’s integrated approach and diversified R&D pipeline position it well to capitalise on Indonesia’s dominant role in the global seaweed market and emerging opportunities in sustainable agriculture and wellness sectors.

Bottom Line?

BP8’s momentum in Indonesia and diversified R&D portfolio set the stage for a pivotal year, but funding and execution risks remain.

Questions in the middle?

  • How will BP8 manage its cash runway given current operating losses and limited reserves?
  • What is the commercial potential and timeline for BP8’s seaweed-based male vitality and bio-stimulant products?
  • Can BP8 scale its independent sales sufficiently to improve margins and reduce reliance on partners?